Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Antiphospholipid Syndrome Clinical Trials

5 recruiting trials for Antiphospholipid Syndrome. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT07236762

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 1 / Phase 2NCT06828042

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage. Autoimmune diseases encompass a wide...

Sponsor: Peking University Third HospitalEnrolling: 91 location
RECRUITINGNCT06614270

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of Anti-CD19 IL-10/IL15 CAR-NK cells...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 151 location
RECRUITINGNCT04402086

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Sponsor: Yale UniversityEnrolling: 50001 location
RECRUITINGPhase 2NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Sponsor: Peking University People's HospitalEnrolling: 501 location